Amyotrophic lateral sclerosis may involve an autoimmune component — a finding that could reshape treatment strategies and ...

ALS may be linked to the immune system, which could explain differences in survival and open doors for new treatments.

While drugs are on the market to slow the progression of neurodegenerative diseases, there are still no cures. But researchers at Boston Children’s Hospital and Harvard Medical School are looking for ...

There are hardly any drugs against ALS. A new study shows that a substance acting on the MAPK signaling pathway may be effective against the neurodegenerative disease: After treatment with trametinib, ...

Eikonizo Therapeutics, a biopharmaceutical company developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases, today announced the ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

The pathway leading to the telltale sign of ALS, protein aggregation in the cytoplasm of motor neurons, has been revealed. Researchers from the University of California – San Diego (CA, USA) have ...

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of ...

SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® ...

While the overall trial did not meet its primary and secondary endpoints, Neuronata-R ® showed meaningful efficacy in patients with slower disease progression. These findings confirm Neuronata-R ® 's ...